Avalo Therapeutics, Inc.
AVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534120
In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Avalo Therapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 97 | 126 | +29 |
| Shares | 31.5M | 70.8M | +39.3M (+124.9%) |
| Value | $469.6M | $1.31B | +$838.0M (+178.5%) |
New holders (56)
Institutions that held Avalo Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
Sold out (27)
Institutions that held Avalo Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.